It is now well established that long peptide vaccines are preferred to single CD8 epitopes due to their capacity to harbour multiple CD8+ and CD4+ T cell epitopes and bind to a wider range of HLA-haplotypes, thereby increasing their efficiency at generating durable anti-tumour responses (34, 35). This evidence concerns the gene CD8A and neoplasm.